Mechanisms of resistance to CAR T cell therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mechanisms of resistance to CAR T cell therapies

Published:2020-10 Issue: Volume:65 Page:91-98
ISSN:1044-579X
Container-title:Seminars in Cancer Biology
language:en
Short-container-title:Seminars in Cancer Biology

Author:

Singh Nathan,Orlando Elena,Xu Jun^ORCID,Xu Jie,Binder Zev^ORCID,Collins McKensie A.,O’Rourke Donald M.,Melenhorst J. Joseph

Funder

Novartis Institutes for Biomedical Research

Parker Institute for Cancer Immunotherapy

Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

Publisher

Elsevier BV

Subject

Cancer Research

Reference92 articles.

1. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19;Kochenderfer;Blood,2010

2. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N. Engl. J. Med.,2011

3. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia;Kalos;Sci. Transl. Med.,2011

4. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N. Engl. J. Med.,2014

5. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N. Engl. J. Med.,2018

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer;Translational Oncology;2024-12

2. Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy;Journal of Hematopathology;2024-08-26

3. GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma;Acta Pharmacologica Sinica;2024-05-15

4. Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data;Frontiers in Pharmacology;2024-01-24

5. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS;Blood;2024-01-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3